Biologics News

Editor’s Note: This article by Enrique Gómez Barrena, MD, Vice Chairman Education Committee – Basic Research Group of EFORT, is the first in a series of articles in Orthopedics Today Europe about the Basic Research Group’s activities.

One year of testosterone treatment significantly increased volumetric bone mineral density and estimated bone strength in men aged 65 years and older, according to data published in JAMA Internal Medicine.

Zimmer Biomet Holdings Inc. announced the international release of the subchondroplasty procedure, a minimally invasive outpatient procedure to treat defects associated with subchondral bone marrow lesions, according to a company press release.

Orthocell Limited announced a research collaboration agreement with DePuy Synthes Products Inc., part of the Johnson & Johnson Family of Companies, on its Ortho-ATI stem cell approach to regenerate degenerated tendons and ligaments. According to a press release, the partnership was facilitated by Johnson & Johnson Innovation.

Are you challenged by the need to achieve bone healing in an infected environment or, as a knee surgeon, do you have to evaluate the different types of knee replacement surgery that are possible for every patient? If so, two Interactive Expert Exchange (IEE) sessions at the upcoming EFORT Congress in Vienna will provide a deeper understanding of these topics and present various options for the orthopaedic surgeon’s daily practice.

Recently published results showed running not only decreased knee intra-articular ulnar pro-inflammatory cytokine concentration, but also facilitated the movement of cartilage oligomeric matrix protein from the joint space to the serum.

Sanford Health is conducting the first clinical trial approved by the FDA to treat injured shoulders using patients’ adipose stem cells.

The FDA has released a draft guidance for industry outlining criteria for demonstrating that a biosimilar is interchangeable with a reference product under section 351 (k) of the Public Health Service Act.

The FDA has released its final guidance for the naming of biological products, which recommends distinct names and suffixes for both biosimilars and reference products, according to a press release from the American College of Rheumatology.

Lipogems announced it has received an FDA 510(k) clearance for expanded indications and labelling of its Lipogems System for adipose tissue transfer.